Drug Trial Radar · NCT04972227
Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia
Last checked: Nov 19, 2026Latest source record: Aug 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Sep 10, 2021
Primary completion
Apr 18, 2022
Study completion Apr 18, 2022
Sponsor
- Lead sponsor
- Tisento TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jul 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the safety and tolerability of CY6463 when administered to participants with stable schizophrenia who are on a stable antipsychotic medication regimen
Conditions
- Schizophrenia
Interventions
CY6463Drug
oral tablets
PlaceboDrug
oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and TEAEs leading to study drug discontinuationTime frame: 28 (±4) days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Collaborative Neuroscience Network
Long Beach, California
Hassman Research Institute
Marlton, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.